- document
- Stokman, G. (author), van den Hoek, A.M. (author), Denker Thorbekk, D. (author), Pieterman, E.J. (author), Skovgård Veidal, S. (author), Basta, B. (author), Iruarrizaga-Lejarreta, M. (author), van der Hoorn, J.W. (author), Verschuren, L. (author), Berbée, J.F.P. (author), Rensen, P.C.N. (author), Skjæret, T. (author), Alonso, C. (author), Feigh, M. (author), Kastelein, J.J.P. (author), Friedman, S.L. (author), Princen, H.M.G. (author), Fraser, D.A. (author) article 2020
- document
-
van den Hoek, A.M. (author), Pieterman, E.J. (author), van der Hoorn, J.W. (author), Iruarrizaga-Lejarreta, M. (author), Alonso, C. (author), Verschuren, L. (author), Skjæret, T. (author), Princen, H.M.G. (author), Fraser, D.A. (author)Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH). In this study, we investigated the absorption and distribution properties of icosabutate in relation to liver targeting and used rodents to evaluate the effects of icosabutate on glucose metabolism, insulin...article 2020
- document
-
van de Steeg, E. (author), Läppchen, T. (author), Aguilera, B. (author), Jansen, H.T. (author), Muilwijk, D. (author), Vermue, R. (author), van der Hoorn, J.W. (author), Donato, K. (author), Rossin, R. (author), de Visser, P.C. (author), Vlaming, M.L.H. (author)Antisense oligonucleotides (AONs) are promising candidates for treatment of Duchenne muscular dystrophy (DMD), a severe and progressive disease resulting in premature death. However, more knowledge on the pharmacokinetics of new AON drug candidates is desired for effective application in the clinic. We assessed the feasibility of using...article 2017
- document
-
Vlaming, M.L.H. (author), Läppchen, T. (author), Jansen, H.T. (author), Kivits, S. (author), van Driel, A. (author), van der Steeg, E. (author), van der Hoorn, J.W. (author), Sio, C.F. (author), Steinbach, O.C. (author), de Groot, J. (author)Introduction: The efflux transporters P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP, ABCG2) are expressed at the blood-brain barrier (BBB), and can limit the access of a wide range of drugs to the brain. In this study we developed a PET-CT imaging method for non-invasive, quantitative analysis of the effect of ABCB1 and...article 2015
- document
-
van der Tuin, S.J. (author), Kühnast, S. (author), Berbée, J. (author), Verschuren, L. (author), Pieterman, E.J. (author), Havekes, L.M. (author), van der Hoorn, J.W. (author), Rensen, P.C. (author), Jukema, J.W. (author), Princen, H.M. (author), Willems van Dijk, K. (author), Wang, Y. (author)Recently, we showed in APOE*3-Leiden.CETP mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL-C rather than by raising HDL-C. Here, we investigated the mechanism by which anacetrapib reduces (V)LDL-C and whether this effect was dependent on the inhibition of CETP. APOE*3-Leiden.CETP mice were fed a Western type diet...article 2015
- document
-
Bijland, S. (author), Rensen, P.C.N. (author), Pieterman, E.J. (author), Maas, A.C.E. (author), van der Hoorn, J.W. (author), van Erk, M.J. (author), Havekes, L.M. (author), van Dijk, K.W. (author), Chang, S.C. (author), Ehresman, D.J. (author), Butenhoff, J.L. (author), Princen, H.M.G. (author)Perfluorobutane sulfonate (PFBS), perfluorohexane sulfonate (PFHxS), and perfluorooctane sulfonate (PFOS) are stable perfluoroalkyl sulfonate (PFAS) surfactants, and PFHxS and PFOS are frequently detected in human biomonitoring studies. Some epidemiological studies have shown modest positive correlations of serum PFOS with non-high-density...article 2011
- document
- van der Hoorn, J.W. (author), Bekkers, M.E. (author), Princen, H.M. (author), Corda, S. (author), Emeis, J.J. (author), Steendijk, P. (author), TNO Kwaliteit van Leven (author) article 2008